The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes Care
文献类型：期刊论文
| 作者 | Hilgenfeld, Rolf2,3,4; Seipke, Gerhard1; Berchtold, Harald1; Owens, David R.5 |
| 刊名 | DRUGS
 |
| 出版日期 | 2014-06 |
| 卷号 | 74期号:8页码:911-927 |
| ISSN号 | 0012-6667 |
| DOI | 10.1007/s40265-014-0226-4 |
| 文献子类 | Review |
| 英文摘要 | The epoch-making discovery of insulin heralded a new dawn in the management of diabetes. However, the earliest, unmodified soluble insulin preparations were limited by their short duration of action, necessitating multiple daily injections. Initial attempts to protract the duration of action of insulin involved the use of various additives, including vasoconstrictor substances, which met with limited success. The subsequent elucidation of the chemical and three-dimensional structure of insulin and its chemical synthesis and biosynthesis allowed modification of the insulin molecule itself, resulting in insulin analogs that are designed to mimic normal endogenous insulin secretion during both fasting and prandial conditions. Insulin glargine was the first once-daily, long-acting insulin analog to be introduced into clinical practice more than 10 years ago and is specifically designed to provide basal insulin requirements. It has a prolonged duration of action and no distinct insulin peak, making it suitable for once-daily administration and reducing the risk of nocturnal hypoglycemia that is seen with intermediate-acting insulins. Insulin glargine can be used in combination with prandial insulin preparations and non-insulin anti-diabetic agents according to individual requirements. |
| WOS关键词 | AMINO-ACID-SEQUENCE ; LONGACTING BASAL INSULIN ; NON-INFERIORITY TRIAL ; TO-TARGET TRIAL ; GROWTH-FACTOR-I ; NPH INSULIN ; PANCREATIC EXTRACTS ; OPEN-LABEL ; HOE 901 ; SUBCUTANEOUS INJECTION |
| 资助项目 | Chinese Academy of Sciences through a Visiting Professorship for Senior International Scientists[2010T1S6] ; Sanofi[00000000] |
| WOS研究方向 | Pharmacology & Pharmacy ; Toxicology |
| 语种 | 英语 |
| WOS记录号 | WOS:000344616100006 |
| 出版者 | ADIS INT LTD |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/277036]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Hilgenfeld, Rolf |
| 作者单位 | 1.Sanofi Aventis Deutschland GmbH, Frankfurt, Germany; 2.Univ Lubeck, Ctr Struct & Cell Biol Med, Inst Biochem, D-23538 Lubeck, Germany; 3.Univ Lubeck, Ctr Brain Behav & Metab, D-23538 Lubeck, Germany; 4.Shanghai Inst Mat Med, Shanghai, Peoples R China; 5.Swansea Univ, Coll Med, Inst Life Sci, Diabet Res Grp, Swansea, W Glam, Wales |
| 推荐引用方式 GB/T 7714 | Hilgenfeld, Rolf,Seipke, Gerhard,Berchtold, Harald,et al. The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes Care[J]. DRUGS,2014,74(8):911-927. |
| APA | Hilgenfeld, Rolf,Seipke, Gerhard,Berchtold, Harald,&Owens, David R..(2014).The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes Care.DRUGS,74(8),911-927. |
| MLA | Hilgenfeld, Rolf,et al."The Evolution of Insulin Glargine and its Continuing Contribution to Diabetes Care".DRUGS 74.8(2014):911-927. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。